Date | Interest Coverage Ratio | Debt to Equity Ratio | Interest Expense To Sales | Inventory Turnover Ratio |
---|
CEO | Mr. Weiyi Shen |
IPO Date | March 9, 2016 |
Location | China |
Headquarters | Xianju modern industrial cluster |
Employees | 1,845 |
Sector | Health Care |
Industries |
Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.
Past 5 years
USD 3.33
USD 1.67
USD 2.19
USD 1.78
USD 2.17
StockViz Staff
January 15, 2025
Any question? Send us an email